202208 NIH HEAL Initiative funding

August 18, 2022: Rural and Remote Populations Are Focus of Funding Opportunity From NIH HEAL Initiative

Posted on by Damon Seils

NIH Heal Initiative logoThe NIH HEAL Initiative℠, or Helping to End Addiction Long-Term Initiative℠, announced its intent to publish a new funding opportunity for cooperative research that will accelerate implementation of nonopioid interventions for chronic pain management in rural and remote populations. The initiative will support pragmatic, implementation, and hybrid effectiveness-implementation trials that study strategies for equitably and efficiently implementing effective interventions and evidence-based pain management guidelines in rural and remote communities.

The funding opportunity announcement is expected to be published in fall 2022, with an expected application due date in winter 2022. Funded projects will become part of the NIH HEAL Initiative’s PRISM (Pragmatic and Implementation Studies to Improve the Management of Pain and Reduce Opioid Prescribing) program.

The NIH Collaboratory Coordinating Center serves as the PRISM Resource Coordinating Center. Six PRISM NIH Collaboratory Trials within the NIH Collaboratory are studying the real-world effectiveness of nonpharmacologic interventions for pain and assessing the implementation of these interventions to improve pain management and reduce reliance on opioids.

Read the complete Notice of Intent to Publish a Funding Opportunity Announcement for HEAL Initiative: Prevention and Management of Chronic Pain in Rural Populations (UG3/UH3, Clinical Trials Required).

August 11, 2022: New Funding Opportunities From NIH HEAL Initiative Will Support Sickle Cell Disease Pain Management

Posted on by Damon Seils

NIH Heal Initiative logoThe Helping to End Addiction Long-Term Initiative℠, or NIH HEAL Initiative℠, recently published 2 funding opportunity announcements soliciting applications focused on sickle cell disease (SCD) pain management. The effort is co-led by the National Center for Complementary and Integrative Health and the National Heart, Lung, and Blood Institute, with support from other NIH Institutes, Centers, and Offices.

  • RFA-AT-23-001, “HEAL Initiative: Pragmatic and Implementation Studies for the Management of Sickle Cell Disease Pain” (UG3/UH3, Clinical Trials Optional) will support multisite embedded pragmatic or implementation trials to inform the uptake of pharmacologic, nonpharmacologic, and/or multicomponent approaches for acute and/or chronic SCD pain management in healthcare systems that serve the SCD population.
  • RFA-AT-23-002, “HEAL Initiative: Sickle Cell Disease Pain Management Trials Utilizing the Pain Management Effectiveness Research Network Cooperative Agreement” (UG3/UH3, Clinical Trial Required), will support multisite effectiveness clinical trials of pharmacologic, nonpharmacologic, and/or multicomponent approaches for acute and/or chronic SCD pain management, allowing continued opioid pain management as needed.

August 9, 2022: NIH HEAL Initiative Announces Funding Opportunity for Prevention Research in Community Health Centers

Posted on by Damon Seils

NIH Heal Initiative logoThe Helping to End Addiction Long-Term Initiative℠, or NIH HEAL Initiative℠, is seeking applications for opioid misuse prevention research in community health centers.

The funding opportunity announcement, RFA-DA-23-048: HEAL Initiative: Research Studies to Develop and Implement Interventions to Prevent Opioid Misuse in Community Health Centers, supports interdisciplinary teams to study the development, adaptation, and/or implementation of interventions to prevent misuse of opioids and other substances. Research will be supported through exploratory/developmental phase awards that may not exceed 5 years, allocating up to 2 years of funding for development of the project and up to 4 years for a full test of the research aims. Applications are due November 8, 2022.

The National Institute on Drug Abuse will hold a webinar on September 6 for potential applicants. Register for the webinar.  For more information, contact Sarah Steverman at sarah.steverman@nih.gov.